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Abstract
Background: Point mutations in the mitofusin 2 (MFN2) gene has been identified exclusively in Charcot-Marie-
Tooth type 2 (CMT2), and in a single family with intermediate CMT. MFN2 point mutations are probably the most
common cause of CMT2.
Methods: Two-hundred and thirty-two consecutive unselected and unrelated CMT families with available DNA
from all regions in Norway were included. We screened for point mutations in the MFN2 gene.
Results: We identified four known and three novel point mutations in 8 unrelated CMT families. The novel point
mutations were not found in 100 healthy controls. This corresponds to 3.4% (8/232) of CMT families have point
mutations in the MFN2 gene. The phenotypes were compatible with CMT1 in two families, CMT2 in four families,
intermediate CMT in one family and distal Hereditary Motor Neuropathy (dHMN) in one family. This corresponds to
2.3% of CMT1, 5.5% of CMT2, 12.5% of intermediate CMT and 6.7% of dHMN families have a point mutation in the
MFN2 gene. Point mutations in the MFN2 gene is likely to be the fourth most common cause to CMT after
duplication of the peripheral myelin protein 22 (PMP22) gene, and point mutations in the Connexin32 (Cx32) and
myelin protein zero (MPZ) genes.
Conclusions: The identified known and novel point mutations in the MFN2 gene expand the clinical spectrum
from CMT2 and intermediate CMT to also include possibly CMT1 and the dHMN phenotypes. Thus, genetic
analyses of the MFN2 gene should not be restricted to persons with CMT2.
Background
Charcot-Marie-Tooth (CMT) disease is a heterogeneous
group of inherited peripheral neuropathies with an esti-
mated prevalence of 1 in 2,500[1]. At present 40 differ-
ent genes has been identified to cause inherited
peripheral neuropathies[2]. CMT is subdivided into type
1 and 2, depending on whether the motor conduction
velocity (MCV) is less or above 38 m/s[3,4]. A third
form has intermediate MCV[5]. Intermediate CMT is
defined as MCVs between 25 and 45 m/s. Distal Heredi-
tary Motor Neuropathy (dHMN) is the spinal form of
CMT[6].
Twelve different genes have been described to cause
CMT2. The majority of the mutations are reported in
the mitofusin 2 (MFN2) gene[2]. This gene is responsi-
ble for 18-23% of those with CMT2, and is probably the
most common cause of CMT2 [7-9]. A MFN2 mutation
has also been described in a single family with inter-
mediate CMT[9].
Mitofusins are evolutionary conserved GTPases of the
mitochondrial outer membrane, and has an essential
role for the controlled fusion of the mitochondria mem-
brane[10]. The MFN2 protein spans the mitochondrial
outer membrane with a large N-terminal and a relatively
short C-terminal exposed to the cytosol[11]. The MFN2
mutation so far has almost exclusively been missense
mutations that affect the N- or the C-terminal of the
MFN2 protein[2,9].
We analyzed 232 Norwegian CMT families for muta-
tions in the MFN2 gene.
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Patients
Two-hundred and thirty-two consecutive unselected and
unrelated CMT families with available DNA from all
regions in Norway were included. The total Norwegian
population is 4.8 millions people. Based on clinical and
neurophysiological data, 86 families had CMT1 (47.3%),
73 families had CMT2 (40.1%), 8 families had intermedi-
ate CMT (4.4%) and 15 families had dHMN (8.2%). The
neurophysiological phenotype was unknown in 50
families.
Clinical interview, genetic and neurological examination
Probands and their relatives had a semi-structured clini-
cal interview, a genetic and a neurological examination
by geneticist and neurologist GJB. The diagnosis CMT
was based on clinical information and exclusion of
acquired causes of neuropathy such as endocrine,
immunologic, infectious, metabolic, nutritional, toxic
drugs and substances, and connective tissue and para-
neoplastic disorders. Other hereditary disorders with
neuropathy such as Friedreich’s ataxia, hereditary spastic
paraplegia, myotonic dystrophy etc. were also excluded.
All findings were recorded in a neuropathy scheme that
has been used and evaluated in Norway [12-14]. This
scheme had some supplementary items added by GJB.
Cranial nerves, muscle weakness, reflexes and sensation
was scored according to the Neuropathy Impairment
Score (NIS)[15]. Muscle weakness includes neck flexion,
respiratory muscles, and 9 muscle groups in each upper
extremity (UE) and 8 muscle groups in each lower
extremity (LE). The muscle strength is scored linearly,
i.e. normal strength is scored 0 and paralysis is scored 4,
while 25%, 50% and 75% muscle weakness are scored 1,
2 and 3.
Neurophysiology
Standard techniques with surface electrodes were used
for antidromic sensory conduction and orthodromic
motor conduction. Needle electrodes were used, if the
surface electrodes failed to record conduction velocities.
Electromyography (EMG) was performed.
Mutation analysis
Genomic DNA was extracted from white blood cells
using FlexiGene DNA Kit (QIAGEN). The coding exons
were derived from the published sequences in National
Center for Biotechnology Information (NP_055689 and
NM_014874, MFN2). Primers for PCR amplification of
exons and intronic splice junctions were designed with
Primer3[16]. Fifty ng of patient genomic DNA was used
for the analysis. Each region was amplified in 35 cycles.
The sequencing was carried out using the PCR primers,
internal sequencing primers when needed, and BigDye
Terminator kit version 1.1. Sequencing was performed
using Applied Biosystems ABI3130x1 Genetic analyzer
and aligned with the Sequencher programme (Gene
Codes Corporation, Ann Arbor, MI). The numbering of
nucleotides is according to the open reading frame of
the cDNA sequences[17]. In families in which a de novo
point mutation was suspected, paternity was confirmed
using 17 STR markers (CSF1PO, D3S1358, D5S818,
D7S820, D8S1179, D12S392 D13S317, D16S539,
D17S906, D18S51, D21S11, FGA, Penta D, Penta E,
TH01, TPOX, and vWA) and Amelogenin. One-hun-
dred persons without neuropathy were screened as con-
trols for sequence variations. For further details see
Additional file 1.
We analyzed for mutations consecutively in the genes;
peripheral myelin protein 22 (PMP22), Connexin32
(Cx32), myelin protein zero (MPZ), small integral mem-
brane protein of lysosome/late endosome (SIMPLE), early
growth response 2 (EGR2), and MFN2. The PMP22
duplication was investigated by Real-time quantitative
PCR[18]. Coding exons were derived from published
sequences in GenBank (Cx32 (GJB1): NM_000166,
EGR2: NM_000399, MFN2: BC017061, MPZ:
NM_000530, PMP22: NM_000304 and SIM-
PLE_NM_004862, AB034747. Primers for PCR amplifi-
cation of exons and intronic splice junctions were
designed with Primer3[16].
Ethics
The study was approved by the ethical committees. Par-
ticipation was based on informed consent.
Results
Molecular genetic analysis
We screened the entire coding region and the intron/
exon boundaries of the MFN2 gene. A total of 232 unre-
lated Norwegian families with CMT were included. We
identified 7 point mutations in 8 CMT families (Table
1). Four point mutations were known, and three point
mutations were novel. All our point mutations were
missense mutation that caused an amino acid change.
The point mutations were located in exons 4, 14, 15
and 18. The novel point mutations c.1709A>G and
c.2119C>T were found in the probands, while
c.2146G>A was found in the proband and his affected
first cousin. The pedigrees, family 1, 2, 3, 4, 5, 6, 7 and
8a r es h o w ni nf i g u r e1 ,2 ,3 ,4 ,5 ,6 ,7a n d8 ,r e s p e c -
tively. Five pedigrees had a segregation pattern compati-
ble with autosomal dominant inheritance (Figures 1, 5,
6, 7 and 8). In four probands the MFN2 point mutation
occurred de novo. Paternity was confirmed in one pedi-
gree (Figure 2). HLA haplotyping was compatible with
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Page 2 of 8paternity in another family (Figure 1), while DNA was
unavailable in two fathers (Figure 3 and 4). None of the
novel point mutations was found in 200 control chro-
mosomes of healthy Norwegians. However, we found a
c.1569C>T polymorphism in eight persons, that did not
change the amino acid sequence (Ser523Ser). We found
no duplication in PMP22 gene, and no point mutations
in the PMP22, Cx32, MPZ, SIMPLE or EGR2 genes in
the affected with MFN2 missense mutations.
Clinical and neurophysiological findings
Table 2 shows a summary of the neurophysiology and
molecular genetic findings in 232 unrelated Norwegian
CMT families. We identified a MFN2 point mutation in
3.4% (8/232) of the CMT families. The phenotype was
compatible with CMT1 in two probands, CMT2 in four
probands, intermediate CMT in one proband, and distal
Hereditary Motor Neuropathy (dHMN) in one proband.
This corresponds to 2.3% of CMT1, 5.5% of CMT2,
12.5% of intermediate CMT and 6.7% of dHMN families
have a point mutation in the MFN2 gene.
The mean age at onset was 3.0 years in the CMT1
probands and 26.3 years in the CMT2 probands, while
the probands with intermediate CMT and dHMN had
late onset (Table 1). The initial symptoms were muscle
weakness, difficulties walking and frequent falls. Pes
cavus, hammertoes and muscle wasting in feet and legs
was frequently observed (Additional file 2, table S3).
The sensory modality touch and pain were mildly
affected. Vibration and proprioception in the toes,
Table 1 Gender, age at onset, initial symptoms of Charcot-Marie-Tooth disease, phenotype and point mutations in the
eight unrelated Norwegian families with mutation in the MFN2 gene.
Family
no.
Family
member
Gender Age at
onset
(yrs)
Initial symptoms Phenotype Point
mutation
Exon Amino
acid
Change
1 II-2 ♀ 4 Weakness in legs CMT1 c.280C>T 4 Arg94Trp
III-1 ♀ 4 Weakness in legs and pes cavus
2 II-1 ♀ 4 Stumble and dorsal motion weakness in toes CMT2 c.281G>A 4 Arg94Gln
3 II-1 ♂ 2 Foot deformity and stumbled CMT1 c.1403G>A 14 Arg468His
4 II-1 ♂ 63 Weakness in the right foot, and difficulties
walking
dHMN c.1709A>G 15 Asn570Ser
5 III-9 ♀ 10 Weakness in legs and pes cavus CMT2 c.2113G>A 18 Val705Ile
6 II-3 ♂ 47 Paresthesia in feet CMT2 c.2113G>A 18 Val705Ile
7 III-3 ♂ 44 Muscular pain during exercise in left leg CMT2 c.2119C>T 18 Arg707Trp
8 III-2 ♂ 23 Recurrent ankle sprains, weakness and reduced
balance
Intermediate
CMT
c.2146G>A 18 Ala716Thr
III-4 ♂ 50 Paresthesia in foot
Relatives of probands and novel point mutations are shown in italics.
Figure 1 Pedigree of family 1 with point mutation in the MFN2
gene.
Figure 2 Pedigree of family 2 with point mutation in the MFN2
gene.
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quently affected. Muscle weakness in the lower limbs
varied considerable (Additional file 3, table S4). One
proband was wheelchair bound, while her daughter had
severe difficulties walking (Family 1). Additional features
such as tremor in arm/leg and kyphoscoliosis were
sometimes present (Additional file 2, table S3).
The proband in family 4 had a complex history prior
to weakness of the right foot and walking difficulties at
age 63 years. At age 57 years he had a L4 compression
fracture causing spinal stenosis and intermittent claudi-
catio, until he had a laminectomy, facetectomy and dis-
cectomy two years later. A 1/2 year later he experienced
lumbar pain and paresthesia in the thighs and had a
new laminectomy at age 63 years. One year prior he had
bilateral arthroplasty due to osteoarthrosis. He was
operated for an abdominal aortic aneurism at age 65
years and four years later he had radiotherapy for a
prostate cancer.
Neurophysiological data were available from eight pro-
bands and one relative (Additional file 3, table S4). The
conduction velocities (CV) were reduced in the pro-
bands with the CMT1 phenotypes (Family 1 and 3). The
slight reduction in peroneal motor nerve CV within four
years could be compatible with demyelination, but we
interpreted it as CMT2, see discussion for details
(Family 2). The proband in family 4 had normal motor
and sensory CV and chronic denervation compatible
with dHMN. The CV were slightly reduced but >38 m/s
in the probands with CMT2 phenotypes (Family 5-7).
T h er a n g eo ft h eC Vi nf a m i l y8i sc o m p a t i b l ew i t h
intermediate CMT phenotype. The compound motor
action potential (CMAP) and sensory nerve action
potential (SNAP) was generally reduced or could not be
elicited.
Discussion
We screened 232 unselected and unrelated Norwegian
CMT families with available DNA. A total of 7 MFN2
missense mutations were identified in 8 families (Table
1). The literature describes three nonsense mutations
and one deletion, but missense mutations in far the
most common types of mutations in the MFN2 gene
[2,9,19].
We identified 4 de novo mutations in the MFN2 gene,
paternity could not be confirmed in two families (family
3 and 4) due to lack of paternal DNA. Our 25-50% (2-
4/8) frequency of de novo mutations in an population
sample corresponds well with the 34% and possibly 55%
frequency found in a major collaboration on MFN2
mutations[2]. Two of our de novo missense mutation
occurred in codon 94. The literature describes 5 other
families with de novo mutations in codon 94 with con-
firmed paternity[9,20]. These mutations have also been
described in families with different ethnicity[2]. This
strongly suggest that codon 94 is a hot spot for muta-
tions. The de novo c.1403G>A mutation has previously
been described in three CMT families, but it was also
found in a healthy control[2,21,22]. The c.2113G>A was
found in two unrelated Norwegian families, and has also
been described by others[2,21]. The c.1709A>G in exon
Figure 3 Pedigree of family 3 with point mutation in the MFN2
gene.
Figure 4 Pedigree of family 4 with point mutation in the MFN2
gene.
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tion found in the proband. Mutations in exon 15 have
not previously been described. The other novel missense
mutations were found in probands from CMT families
with several affected, but we only had DNA from a sin-
gle first cousin whom also carried the mutation. We
excluded duplication of PMP22 and point mutation in
PMP22, Cx32, MPZ, SIMPLE and EGR2 genes in the
affected with MFN2 missense mutations.
Previous mutations in the MFN2 gene have all been
assigned to a CMT2 phenotype, except from a single
family that was assigned intermediate CMT[2,7-9,19-21].
Additional symptoms such as ataxia, optic neuritis, optic
atrophy, pyramidal signs, scoliosis and tremor have also
been described[2,23-25].
Missense mutations in codon 94, i.e. amino acid
change Arg94Trp and Arg94Gln cause intermediate
CMT, CMT2 or CMT2 with additional features[9]. The
proband in the family with intermediate CMT had
motor CV <38 m/s in all tested motor nerves including
median nerve and should therefore be classified CMT1.
However, his affected father had motor CV >38 m/s,
and the family was classified intermediate CMT. The
missense mutation Arg94Trp occurred de novo in our
family 1. Since we had no neurophysiological data on
the probands affected daughter, we classified the family
CMT1 rather than the more infrequent intermediate
CMT. The missense mutation in codon 468, i.e amino
Figure 5 Pedigree of family 5 with point mutation in the MFN2 gene.
Figure 6 Pedigree of family 6 with point mutation in the MFN2
gene.
Figure 7 Pedigree of family 7 with point mutation in the MFN2
gene.
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Page 5 of 8acid change Arg468His was f o u n di nap r o b a n dw i t h
CMT2 and her father with Parkinson disease and distal
neuropathy indicating co-segregation as well as in 1 of
260 control chromosomes[21]. A patient with a severe
CMT carried two mutations, the Arg468His in MFN2
and Gln95stop in ganglioside-induced differentiation-
associated protein 1 (GDAP1)[22]. Two family members
carried exclusively the missense mutation in the MFN2
that caused the amino acid change Arg468His. One had
a mild axonal neuropathy at age 56 years, while the
other was unaffected at age 18 years[22]. Three other
family members with the Gln95stop in GDAP1 were
unaffected. The proband in our family 3 with the
Arg468His amino acid change had reduced motor CV,
while 1 of 250 control chromosomes had the missense
mutation carried by an unaffected woman age 25 years.
We analyzed all types of CMT families and found
MFN2 missense mutation in CMT1, CMT2, intermedi-
ate CMT and dHMN patients.
The CV in the median motor nerve is used as refer-
ence for classifying CMT1, CMT2 and intermediate
CMT [3-5]. dHMN is defined with normal motor and
sensory CV and chronic denervation on EMG[6]. We do
not have CV of the median motor nerve in the probands
with CMT1. However, they all had reduced CV in
motor nerves compatible with CMT1. The CV is equal
in the ulnar and the median motor nerve. Thus, the
proband with CV <38 m/s in the ulnar motor nerve was
classified CMT1 (Family 1). We interpreted the marked
reduction in motor CV of the tibial nerve as demyelina-
tion (Family 3). The slight reduction in motor CV of the
peroneal nerve in Family 2 was interpreted as CMT2, as
the CV cut off for the normal value is less in the pero-
neal than the median nerve, and an extrapolation with
this proportional factor would increase the CV from
35.2 to 42.1 m/s, while a similar extrapolation in family
3 would increase the CV from 15.7 to 18.8 m/s (Addi-
tional file 2, table S3). Our neurophysiological data is far
from optimal. The 232 consecutive unselected and unre-
lated CMT families with available DNA were from all
regions in Norway, and were included into the study
irrespective of the perfection of neurophysiological para-
meters, if the clinical or other parameters suggested it
was CMT. An International study of mutations in the
MFN2, included 323 unrelated probands of whom 44
unrelated probands had an unknown neurophysiology
[9]. The lack of complete neurophysiological data makes
the neurophysiological classification a challenge, along
with the fact that CMAP were reduced in several
recordings. Severely reduced CMAP and low CV in
lower limbs suggest CMT2. However, the neurophysio-
logical classification on CMT is based on CV alone not
including CMAP or other neurophysiological features.
For that reason we focused on CV in our interpretation.
This provides a challenge in family 2, 3, 4 and 5 since
neurophysiological data is only available from the lower
limbs. Family 4 is diagnosed as dHMN based on a
motor and a sensory CVs were normal, but the ampli-
tudes of the sensory potentials were not measured
which makes it difficult to judge whether the sensory
nerves were involved or not.
T h eI n t e r n a t i o n a ls t u d yo nMFN2 mentioned above
included 323 unrelated probands, of whom 249 (77%)
probands were diagnosed as CMT2, 20 (6%) had inter-
mediate CMT, six (2%) had CMT1, three (1%) had
dHMN and one (<1%) had hereditary sensory and auto-
nomic neuropathy (HSAN, while 44 (14%) had an
unknown neurophysiological phenotype. MFN2 muta-
tions were found in 28 probands with CMT2 and in one
family with intermediate CMT. We found the MFN2
mutation in 2 of 86 (2.3%) unrelated CMT1 families and
in 1 of 15 (6.7%) unrelated dHMN families. These low
frequencies of MFN2 mutations in CMT1 and dHMN
made it unlikely for the International study to obtain
MFN2 mutations in these CMT subtypes. Unfortunately,
we do not have CV from the median nerve in the two
families classified as CMT1. Thus, further studies are
needed to confirm that MFN2 mutations can cause
CMT1.
Figure 8 Pedigree of family 8 with point mutation in the MFN2
gene.
Table 2 Summary of neurophysiology and MFN2
mutations in 232 CMT families.
Phenotype Neurophysiology
% (n)
MFN2 mutations
% (frequency)
CMT1 37.1 (86) 2.3 (2/86))
CMT2 31.5 (73) 5.5 (4/73)
Intermediate CMT 3.4 (8) 12.5 (1/8)
dHMN 6.5 (15) 6.7 (1/15)
CMT neurophysiology unknown 21.6 (50) 0 (0/50)
Total 100 (232) 3.4 (8/232)
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families (Family 1 and 3), while it was late in CMT2,
intermediate and dHMN (Family 4-8), with one excep-
tion (Family 2). Additional symptoms such as ataxia,
kyphoscoliosis and tremor were found three families
(Table 2). The phenotype genotype correlation can be
questioned in the proband with dHMN, since the classi-
fication was based on single motor and sensory nerve
and he had multiple other disorders that might have
caused his motor and sensory symptoms (for details see
result section). However, since the motor and sensory
CVs were normal, we characterized the proband as
dHMN. The identified missense mutation c.1709A>G in
exon 15 might be a polymorphism, although we did not
find the mutation among 200 control chromosomes.
Point mutations in the MFN2 gene is likely to be the
fourth most common cause to CMT after the duplica-
tion of PMP22 gene, and point mutations in the Cx32
and MPZ genes. We found that 2.3% of CMT1, 5.5% of
CMT2, 12.5% of intermediate CMT and 6.7% of dHMN
families have a point mutation in the MFN2 gene. We
analyzed for mutations in five other common genes that
may cause CMT1, CMT2, intermediate CMT or dHMN.
However the exclusion analyses were not exhaustive
since mutations in at least 40 genes can cause CMT.
We suggest that genetic analyses of MFN2 should not
be restricted exclusively to those with a CMT2
phenotype.
Conclusions
T o d a yo n l yp e o p l ew i t hC M T 2r e c e i v et e s t i n gf o rt h e
MFN2 gene, as the literature provides no evidence for
testing other subtypes of CMT. Our main finding indi-
cates that MFN2 mutations might be found in all sub-
types of CMT. Thus, MFN2 gene testing should not be
restricted to CMT2.
Additional file 1: Appendix 1. Primer sequences used for amplifying
and sequencing the coding regions of the MFN2 gene.
Additional file 2: Table S3. Clinical characteristics of the patients with
point mutations in the MFN2 gene.
Additional file 3: Table S4. Neurophysiology in patients with Charcot-
Marie-Tooth disease caused by point mutations in the MFN2 gene.
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